id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-D-0307-0064,FDA,FDA-2012-D-0307,Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components,Other,Guidance,2020-06-17T04:00:00Z,2020,6,2020-06-17T04:00:00Z,,2024-11-06T23:37:22Z,,1,0,09000064846f63b5
FDA-2012-D-0307-0063,FDA,FDA-2012-D-0307,"Recommendations To Reduce the Possible Risk of Transmission of
Creutzfeldt-Jakob Disease and Variant Creutzfeldt Jakob Disease by Blood and Blood Components; Guidance for Industry; Availability;",Notice,Notice of Availability,2020-06-17T04:00:00Z,2020,6,2020-06-17T04:00:00Z,,2020-06-17T12:33:02Z,2020-13055,0,0,09000064846f5d22
FDA-2012-D-0307-0055,FDA,FDA-2012-D-0307,Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components Guidance for Industry,Other,Guidance,2020-04-03T04:00:00Z,2020,4,2020-04-03T04:00:00Z,,2024-11-06T23:34:05Z,,1,0,090000648448596f
FDA-2012-D-0307-0056,FDA,FDA-2012-D-0307,29 Reference 29 Holmquest et al. No evidence of transfusion transmitted sporadic CJD,Supporting & Related Material,Background Material,2020-04-03T04:00:00Z,2020,4,,,2020-04-03T14:35:47Z,,0,0,09000064844859c1
FDA-2012-D-0307-0037,FDA,FDA-2012-D-0307,Reference 26- Development of Dose-Response Models of Creutzfeldt-Jakob Disease Infection in Nonhuman Primates re Amendment to ‘‘Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;’’ Draft Guidance for Industry; Availability,Supporting & Related Material,Background Material,2020-02-25T05:00:00Z,2020,2,,,2020-02-25T16:03:56Z,,0,0,09000064843ae6d8
FDA-2012-D-0307-0038,FDA,FDA-2012-D-0307,Reference 33- The New England Journal of Medicine re Amendment to ‘‘Revised Preventive Measures To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products; Guidance for Industry;’’ Draft Guidance for Industry; Availability,Supporting & Related Material,Background Material,2020-02-25T05:00:00Z,2020,2,,,2020-02-25T16:04:02Z,,0,0,09000064843ae6d7
FDA-2012-D-0307-0031,FDA,FDA-2012-D-0307,Recommendations To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt Jakob Disease by Blood and Blood Components;  Draft Guidance for Industry; Availability,Notice,Notice of Availability,2020-01-31T05:00:00Z,2020,1,2020-01-31T05:00:00Z,2020-04-01T03:59:59Z,2020-02-25T13:29:12Z,2020-01815,0,0,0900006484315e30
FDA-2012-D-0307-0032,FDA,FDA-2012-D-0307,Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components; Draft Guidance for Industry,Other,Guidance,2020-01-30T05:00:00Z,2020,1,2020-01-30T05:00:00Z,,2024-11-12T23:16:48Z,,1,0,0900006484317192